Illumina jumps as bullish analyst note extends optimism around clinical sequencing momentum

Illumina, Inc. (ILMN) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a fresh wave of bullish sell-side commentary that highlighted improving confidence in Illumina’s clinical sequencing outlook and consumables pricing power. The stock may also be benefiting from investors continuing to price in the company’s recently improved execution and higher 2026 outlook.

Details:

Guggenheim raised its price target on IllMN to $180 from $170 while keeping a Buy rating, following recent investor meetings with Illumina’s CFO and investor relations team that focused on clinical growth, consumables pricing, and the product pipeline.

Illumina’s Q1 fiscal 2026 update (April 30, 2026) showed revenue of $1.09 billion (up 4.8% year over year) and non-GAAP diluted EPS of $1.15.

Management raised full-year fiscal 2026 guidance, including non-GAAP diluted EPS to $5.15–$5.30 (from $5.05–$5.20) and revenue to $4.52–$4.62 billion (a $20 million midpoint increase).

Illumina’s board authorized an additional $1.5 billion in share repurchases on April 28, 2026, which can support sentiment around shareholder returns.

Sources:

Illumina, Investing.com, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ILMN Insider Trading Activity

$ILMN insiders have traded $ILMN stock on the open market 35 times in the past 6 months. Of those trades, 1 have been purchases and 34 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:

KEITH A. MEISTER has made 0 purchases and 26 sales selling 999,056 shares for an estimated $154,974,605.
SCOTT D ERICKSEN (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $305,150.
SCOTT M DAVIES (Chief Legal Officer) has made 0 purchases and 3 sales selling 2,274 shares for an estimated $297,573.
PATRICIA LECKMAN (SVP, Chief People Officer) sold 2,370 shares for an estimated $275,346
CHRISTENSEN JAKOB WEDEL (SVP, Strategy/Corp Development) has made 0 purchases and 2 sales selling 1,249 shares for an estimated $168,297.
SCOTT GOTTLIEB purchased 200 shares for an estimated $23,562

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ILMN Hedge Fund Activity

We have seen 385 institutional investors add shares of $ILMN stock to their portfolio, and 468 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 4,551,213 shares (-22.6%) from their portfolio in Q1 2026, for an estimated $560,982,514
WCM INVESTMENT MANAGEMENT, LLC added 1,851,848 shares (+45.5%) to their portfolio in Q1 2026, for an estimated $228,258,784
INVESCO LTD. added 1,352,731 shares (+97.0%) to their portfolio in Q4 2025, for an estimated $177,424,197
LOOMIS SAYLES & CO L P removed 1,228,743 shares (-29.5%) from their portfolio in Q1 2026, for an estimated $151,454,862
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. added 863,721 shares (+inf%) to their portfolio in Q1 2026, for an estimated $106,462,250
ALLIANCEBERNSTEIN L.P. added 854,747 shares (+360.9%) to their portfolio in Q1 2026, for an estimated $105,356,115
JUPITER ASSET MANAGEMENT LTD added 816,436 shares (+300.9%) to their portfolio in Q1 2026, for an estimated $100,633,901

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ILMN Government Contracts

We have seen $32,547,815 of award payments to $ILMN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ILLUMINA REAGENT CHEMISTRY KITS: $1,368,526
ILLUMINA REAGENTS AND CONSUMABLES: $999,049
PURCHASE OF 7 MISEQ I100S TO PERFORM WHOLE GENOME SEQUENCING (WGS) ON ALL FOODBORNE PATHOGENS ISOLATED AND ...: $805,796
ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $663,214
EASTERN LAB, MIDWEST LAB, WESTERN LAB QUARTER FOUR FY25 TASK ORDER FOR WGS KITS UNDER CONTRACT 1232SA25D000...: $625,942

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ILMN Congressional Stock Trading

Members of Congress have traded $ILMN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 02/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ILMN Analyst Ratings

Wall Street analysts have issued reports on $ILMN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stifel issued a "Buy" rating on 01/20/2026

To track analyst ratings and price targets for $ILMN, check out Quiver Quantitative's $ILMN forecast page.

$ILMN Price Targets

Multiple analysts have issued price targets for $ILMN recently. We have seen 10 analysts offer price targets for $ILMN in the last 6 months, with a median target of $147.5.

Here are some recent targets:

Subbu Nambi from Guggenheim set a target price of $180.0 on 06/01/2026
Dan Leonard from RBC Capital set a target price of $170.0 on 05/15/2026
Patrick Donnelly from Citigroup set a target price of $95.0 on 05/04/2026
Vijay Kumar from Evercore ISI Group set a target price of $155.0 on 05/01/2026
Casey Woodring from JP Morgan set a target price of $125.0 on 05/01/2026
Luke Sergott from Barclays set a target price of $122.0 on 05/01/2026
Kyle Mikson from Canaccord Genuity set a target price of $140.0 on 05/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.